|Home | About | Journals | Submit | Contact Us | Français|
Lifestyle interventions produce short-term improvements in glycemia and cardiovascular disease (CVD) risk factors in individuals with type 2 diabetes, but no long-term data are available. We examined the effects of a lifestyle intervention on changes in weight, fitness and cardiovascular (CVD) risk factors over 4 years.
Look AHEAD is a multi-center randomized clinical trial comparing the effects of intensive lifestyle intervention (ILI) and diabetes support and education (DSE, control group) on the incidence of major CVD events in 5145 individuals with type diabetes, aged 45 to 76 years, who were overweight or obese (BMI > 25 kg/m2). Participants have ongoing intervention and annual assessments.
Averaged across four years of follow-up, participants in ILI had greater percent weight losses than those in DSE (−6.15% vs −0.88%, p<.0001) and greater improvements in fitness (12.74% vs. 1.96%, p < .0001), HbA1c (A1c, −0.36% vs. 0.09%, p<.0001), systolic blood pressure (SBP, −5.33 vs. −2.97 mmHg, p<.0001), diastolic blood pressure (DBP, −2.92 vs. −2.48 mmHg, p<.012), HDL-cholesterol (HDL-C, 3.67 vs. 1.97 mg/dl, p<.0001), and triglycerides (−25.56 vs. −19.75 mg/dl, p<.0006). Reductions in LDL-C were greater in DSE than ILI (−11.27 vs. −12.84 mg/dl, p=.009), but adjusted for medication use, changes in LDL-C did not differ between the two groups. Although the greatest benefits were often seen at 1 year, ILI participants still had greater improvements than DSE in weight, fitness, HbA1c, SBP, and HDL-C at 4 years.
Intensive lifestyle intervention can produce and maintain significant weight losses and improvements in fitness in individuals with type 2 diabetes. Across four years of follow-up, those in ILI had better overall levels of glycemic control, blood pressure, HDL-C and triglycerides, and thus spent considerable time with lower CVD risk. Whether this translates to reduction in CVD events will ultimately be addressed by the Look AHEAD study.
Improving glycemic control and cardiovascular disease risk factors in the population with type 2 diabetes is critical for prevention of long-term vascular complications of the disease. This has led to increased emphasis on screening and medical management of blood pressure, lipids, and glycemic control. Lifestyle-based weight loss interventions are also recommended to improve glycemic control and risk factors, but the evidence supporting the efficacy of lifestyle approaches is limited to short-term studies of typically under one year.1–4 With recent improvements in behavioral weight loss interventions5, 6 and increased recognition of the impact of lifestyle approaches for prevention of diabetes, it is timely to examine the longer term effects of these interventions on changes in glycemic control and cardiovascular risk factors in individuals with diabetes.
The Look AHEAD (Action for Health in Diabetes) Study is examining the long-term impact of an intensive lifestyle intervention, compared with usual care, on cardiovascular morbidity and mortality in 5,145 overweight or obese individuals with type 2 diabetes.7 We have previously reported on the beneficial effects of the lifestyle intervention at one year.1 This report examines the changes in weight, fitness, glycemic control and cardiovascular disease (CVD) risk factors over 4 years for participants in the intensive lifestyle intervention compared with diabetes support and education.
As reported previously,7 participants for Look AHEAD were recruited at 16 centers in the United States and were required to be 45–76 years of age (increased to 55–75 years in year 2 of randomization) and to have a BMI of ≥25 (≥27 in patients on insulin), HbA1c <11%, SBP <160 mmHg, DBP <100 mmHg, and triglycerides 003C600 mg/dl. The goal was to recruit approximately equal numbers of men and women and > 33% from racial and ethnic minority groups. Participants were required to successfully complete a maximal graded exercise test, two weeks of self-monitoring, and attend a Look AHEAD diabetes education session. All participants signed a consent form approved by their local Institutional Review Board (IRB).
Participants were randomly assigned by center to Intensive Lifestyle Intervention (ILI) or Diabetes Support and Education (DSE). The intensive lifestyle intervention8 included diet modification and physical activity and was designed to induce at least a 7% weight loss at year 1 and to maintain this weight loss in subsequent years. ILI participants were assigned a calorie goal (1200–1800 based on initial weight), with <30% of total calories from fat (< 10% from saturated fat) and a minimum of 15% of total calories from protein. To increase dietary adherence, a portion-controlled diet was used, with liquid meal replacements provided free and recommendations to use other portion-controlled items. The goal was at least 175 minutes of physical activity per week, using activities similar in intensity to brisk walking. Behavioral strategies, including self-monitoring, goal setting and problem solving were stressed.
Participants in ILI were seen weekly for the first 6 months and 3 times per month for the next 6 months, with a combination of group and individual contacts. During years 2–4, participants were seen individually at least once a month, contacted another time each month by phone or e-mail, and offered a variety of centrally-approved group classes. At each session, participants were weighed, self-monitoring records were reviewed, and a new lesson was presented, following a standardized treatment protocol.
Participants in DSE were invited to three group sessions each year. These sessions utilized a standardized protocol and focused on diet, physical activity, or social support. Information on behavioral strategies was not presented and participants were not weighed at these sessions.
For participants in both ILI and DSE, the participant’s own physicians provided all medical care and made changes in medications, with the exception of temporary changes in diabetes medication during periods of intensive weight loss in ILI.
Assessments were completed annually and a $100 honorarium was provided. All measures were obtained by certified staff masked to the participants’ intervention assignment. Weight and height were measured in duplicate using a digital scale and stadiometer. Blood pressure was measured in duplicate using an automated device. All blood work was completed after at least a 12-h fast and was analyzed by the Central Biochemistry Laboratory (Northwest Lipid Research Laboratories, University of Washington, Seattle, WA) using standardized laboratory procedures for measuring HbA1c, total cholesterol, HDL-C, and triglycerides. LDL-C was estimated using the Friedewald equation.9 Participants brought all their prescription medications to their assessments to accurately record use of medications. A maximal graded exercise test was administered at baseline and a submaximal exercise test at years 1 and 4.10 Changes in fitness were computed as the difference between estimated METS when the participants achieved or exceeded 80% of age-predicted maximal heart rate or an RPE of ≥ 16 at baseline and at the subsequent assessment.
Means reported at baseline are unadjusted averages. All tests of group differences were based on the intent-to-treat principle. Mixed effects analysis of covariance models were used to obtain adjusted mean changes for each outcome at annual visits 1–4, except fitness which was measured only at years 1 and 4. For binary outcomes, generalized estimating equation (GEE) models were used. The intervention effect was estimated as the average difference between arms across all visits, with baseline level of the outcome, clinical center, an indicator of visit for the repeated outcome measures, and intervention assignment included in the model. Adjustment for post-randomization medication use was done using an indicator for use of medication at each follow-up visit. The LDL cholesterol data are presented with and without adjustment for medication use, since this is the only outcome where adjusting for medication use affected the findings. The mixed effects maximum likelihood and GEE analysis of repeated outcomes was carried out in Proc Mixed of SAS, Version 9, using a 0.05 alpha level. An unstructured covariance matrix was used to account for correlation between repeated outcomes, except for triglycerides which required a first order autoregressive structure.
A total of 5145 participants were randomized: 2570 to ILI and 2575 to DSE. The baseline characteristics of these participants have been described in detail.11 Overall, 59% of the participants were women; 37% were from racial or ethnic minorities; 14% reported a history of CVD at baseline, the average age was 58.7 ± 6.8 (Mean ± SD), and the average BMI was 36 ± 5.9 kg/m2. Over 93% of participants were assessed at each of the four years (Fig 1).
Averaged over the four years, participants in ILI experienced significantly greater improvements in weight, fitness, glycemic control, blood pressure, HDL-C and triglycerides than those in DSE (Table 1). The DSE group experienced greater overall reductions in LDL-C but after adjusting for medication use, changes in LDL-C did not differ between ILI and DSE.
Changes in weight and risk factors for DSE and ILI participants at each of the 4 years are shown in Figure 2 (see Appendix 1 for detailed data). Weight losses in ILI were significantly greater than in DSE at each year. The mean maximal weight loss (8.6%) for the ILI group was reached at year 1 and participants in ILI maintained a mean weight loss of 4.7% compared with 1.1% in DSE at 4 years (p<.0001).
Between baseline and year 1, fitness increased by 20.4% in ILI participants and by 5.0% in DSE (p<.0001). At year 4, the fitness level of ILI participants was still 5.1% over baseline, whereas DSE participants were 1.1% below baseline (p<.0001)
Although the differences in HbA1c between groups were greatest at year 1, the ILI group had significantly greater reductions than DSE at each of the 4 years (Fig 2; all p-values <.001). The greater improvements in HbA1c in ILI occurred despite their lower use of diabetes drugs (Table 2). Among those not using any diabetes drug (insulin or oral agents) at baseline, a larger proportion of DSE compared with ILI participants started on these medications each year. Likewise, among those using diabetes medications at baseline, more participants remained on these medications in DSE than in ILI. The same pattern occurred for those using insulin.
Participants in ILI achieved significantly greater reductions in SBP than participants in DSE at all 4 years. However, the magnitude of the difference between arms decreased over time (Figure 2). Likewise improvements in DBP were initially greater in the ILI group than DSE, but differences between groups were no longer significant at year 4 (Table 2). Fewer ILI than DSE participants started on hypertensive medications at years 1, 2, and 3.
HDL-C increased gradually over the 4 years in both DSE and ILI, with significantly greater increases in ILI than in DSE at each time point and a fairly consistent difference between the two groups over the four years (Figure 2). The ILI group also experienced significantly greater reductions in triglycerides during the early years of the study, but the two groups did not differ significantly at year 4.
Both the ILI and the DSE group had significant reductions in unadjusted LDL-C at years 1 and 2, with no significant differences between the two groups. However by years 3 and 4, significant differences emerged in the unadjusted analyses (p<.01), with DSE participants experiencing greater decreases in LDL-cholesterol than ILI. This difference was related to the greater use of lipid lowering medications, specifically statins, in the DSE group (Table 2). After adjusting for use of lipid-lowering medications at baseline and annually, the changes in LDL cholesterol were not significantly different between the ILI and DSE group at any of the 4 years or averaged across the 4 years.
The proportions of participants achieving the ADA goals for HbA1c, BP, and LDL-C in each year of the trial are presented in Table 3. A significantly greater proportion of ILI participants met the ADA goal for HbA1c at each year and for blood pressure at years 1, 2 and 3. The percent of participants achieving the ADA goals for LDL-cholesterol did not differ until year 4, where 65% of DSE participants compared with 61% in ILI (p=.01) met this goal.
Look AHEAD is the first study to examine the effects of an intensive lifestyle intervention through 4 years of follow-up in a large cohort of overweight and obese individuals with type 2 diabetes. This study shows that lifestyle interventions can produce long term weight loss and improvement in fitness and sustained beneficial effects on CVD risk factors. Across the four years, the intensive lifestyle group experienced significantly greater average improvements in all risk factors, except LDL-cholesterol. Although the differences between the two groups was greatest initially and decreased over time for several measures, the differences between the groups averaged over the four years were substantial (Table 1) and indicate that the intervention group spent a considerable time at lower CVD risk.
The average weight losses achieved in the intensive lifestyle intervention at one year (8.6%) were greater than those seen in other multi-center lifestyle trials.5, 12, 13 Although few studies report weight loss data for two or more years of follow-up, the Look AHEAD results at year 2 (6.4%), 3 (5.1%) and year 4 (4.7%) appear comparable or better than those reported previously.5, 14–16 The weight losses in Look AHEAD are impressive in light of the perception that individuals with diabetes have more difficulty losing weight than do their non-diabetic counterparts.17
Maintenance of weight loss has always been a major problem in behavioral treatments of obesity.18, 19 Thus it is interesting to note that weight regain may be slowing over time in Look AHEAD. Whereas participants regained approximately 25% of their weight losses between years 1 and 2 and 20% between years 2 and 3, they regained only 8% of their weight loss between years 3 and 4. The positive effects of the Look AHEAD intervention on weight loss may reflect the ongoing intensive contact,20 combination of group and individual contact, use of meal replacement products, and higher goals prescribed for weight loss.6
Since there have been no intervention studies reporting fitness changes beyond one year for participants with diabetes,21 Look AHEAD provides unique data on long-term changes in fitness. At year 4 the ILI group had maintained a 5% improvement in fitness whereas the control group was below their baseline. The improvements in fitness seen in the ILI group exceed those reported previously for patients with type 2 diabetes in response to a 52 week diet plus exercise intervention.22 The sustained improvements in fitness are important in light of the large number of studies showing that fitness levels are associated with CVD and all-cause mortality.23–26
Averaged across the 4 years, the intervention had significant effects relative to the control group for every cardiovascular risk factor, except LDL-cholesterol. Whereas medications typically address only one risk factor, the lifestyle intervention produced positive changes in glycemic control, blood pressure, and lipids simultaneously. Thus across this time period, participants in the ILI group had lower exposure to a number of potentially negative effects of elevated CVD risk factors.
The improvements in risk factors can also be viewed at each annual visit separately to determine the duration of the effect. Compared with the DSE group, the intervention produced sustained positive effects for four years on glycemic control, systolic blood pressure and HDL-C. The effects on DBP and triglycerides were maintained for only 2–3 years, respectively. We have found no prior intervention studies with individuals with diabetes followed for as long as four years. Based on studies with non-diabetic subjects, the long-term effects of the lifestyle intervention in Look AHEAD are consistent with or greater than those reported previously in other randomized trials with 2 to 3 year follow-up periods or in meta-analyses for blood pressure,13, 27, 28 triglycerides,14, 15, 28 and HDL-C.14, 15, 29
The impact of the intervention on several of the risk factors (HbA1c and SBP) was greatest at year 1, followed by recidivism toward baseline levels. This pattern is likely due in part to the regain of weight and decreases in changes in fitness from years 1 to 4. It may also relate to the stronger effect of weight loss on CVD risk factors immediately after weight loss than at longer time intervals even in those who maintain their weight loss in full.30, 31 In the Swedish Obesity Study (SOS) much larger weight losses achieved through gastric surgery led to short-term improvements in CVD risk factors, which were not necessarily sustained long-term;32 despite this, there were marked benefits of weight loss on cardiovascular mortality.33 The decrease in the beneficial effects of lifestyle, relative to DSE, over the four years for measures such as DBP was also due to the improvements that occurred in the DSE group. These improvements may reflect secular trends in the treatment of CVD risk factors or the effects of diabetes on body weight,34 joining a clinical trial, and/or the beneficial effects of the educational classes.
In addition to the significant differences between groups in the levels of the CVD risk factors, the intervention also resulted in fewer participants in the lifestyle group starting on medications to achieve this control. This was particularly apparent for diabetes medications, especially insulin. Thus, in addition to health benefits, the intervention may result in both health benefits and cost-savings due to decreased medication use.
Of particular note is the sustained effect of lifestyle intervention on HDL-cholesterol. In contrast to several other risk factors, the effect for HDL-cholesterol of the intensive lifestyle intervention relative to the control group was as great at year 4 as it had been at year 1. At each of the 4 years, HDL-C in the lifestyle group was approximately 8–9% higher than baseline levels, whereas the control group was 3–6% above baseline. Early randomized controlled trials35, 36 showed that the combination of weight loss and increased physical activity had the greatest impact on HDL-cholesterol levels and parallel the type of approach used in Look AHEAD. Given the evidence from the Helsinki Heart Study of a strong association between increases in HDL-C and reduced heart disease,37 the effects of lifestyle intervention on HDL-C may provide important long-term cardiovascular benefit.
The finding from Look AHEAD of greater benefits of lifestyle intervention for HDL-C than for LDL-C is consistent with prior studies.2 Levels of LDL-cholesterol decreased consistently over the four years of follow-up in both groups in Look AHEAD, likely due to the large number of participants in both groups who were started on lipid lowering medications, typically statins and reflecting the increasing emphasis given to treating LDL-cholesterol in individuals with diabetes.38 After adjusting for the use of lipid lowering medications, no significant differences in LDL-cholesterol were observed either initially or at follow-up.
In conclusion, the intensive lifestyle intervention was successful in producing sustained weight losses and improvements in cardiovascular fitness through 4 years of follow-up. The intervention group also experienced significantly greater improvements than the usual care group in all CVD risk factors averaged across this time period, with the exception of LDL-C, where after adjusting for medication use, improvements were similar in the two groups. The lifestyle group in Look AHEAD is being offered ongoing intervention activities in an effort to sustain the improvements in risk factors. The critical question is whether these differences between groups in risk factors will translate into differences in the development of cardiovascular disease. These results will not be available for several additional years. However, we note that the magnitude of the effects we have observed for fitness, HDL-C, HbA1c and blood pressure have been associated with decreased cardiovascular events and mortality in prior medication trials and observational studies.24, 25, 39–41 Moreover, there may be long-term beneficial effects from the four year period in which lifestyle participants have been exposed to lower CVD risk factors as seen in other clinical trials.42, 43 Longer follow-up will allow us to determine whether the differences between groups in cardiovascular risk factors can be maintained and whether lifestyle intervention has positive effects on cardiovascular morbidity and mortality.
Rena R. Wing, PhD; Judy L. Bahnson, BA, CCRP; George A. Bray, MD; Jeanne M. Clark, MD, MPH; Mace Coday, PhD; Caitlin Egan, MS; Mark A. Espeland, PhD; John P. Foreyt, PhD; Edward W. Gregg, PhD; Valerie Goldman, MS, RD; Helen Hazuda, PhD; James O. Hill, PhD; Edward S. Horton, MD; Van S. Hubbard, MD, PhD; John Jakicic, PhD; Robert W. Jeffery, PhD; Karen C. Johnson, MD, MPH; Steven Kahn MB, ChB; Tina Killean, BS; Abbas E. Kitabchi, PhD, MD; Cora E. Lewis, MD, MSPH; Cathy Manus, LPN; Barbara J. Maschak-Carey, MSN, CDE; Sara Michaels, MD; Maria Montez, RN, MSHP, CDE; Brenda Montgomery, RN, MS, CDE; David M. Nathan, MD; Jennifer Patricio, MS; Anne Peters, MD; Xavier Pi-Sunyer, MD; Henry Pownall, PhD; David Reboussin, PhD; W. Jack Rejeski, PhD; Richard Rubin, PhD; Monika Safford, MD; Tricia Skarphol, MA; Brent Van Dorsten, PhD; Thomas A. Wadden, PhD; Lynne Wagenknecht, DrPH; Jacqueline Wesche-Thobaben, RN, BSN, CDE; Delia S. West, PhD; Donald Williamson, PhD; Susan Z.Yanovski, MD
Frederick L. Brancati, MD, MHS1; Lee Swartz2; Lawrence Cheskin, MD3; Jeanne M. Clark, MD, MPH3; Kerry Stewart, EdD3; Richard Rubin, PhD3; Jean Arceci, RN; Suzanne Bau; Jeanne Charleston, RN; Danielle Diggins; Mia Johnson; Joyce Lambert; Kathy Michalski, RD; Daron Niggetts; Chanchai Sapun
George A. Bray, MD1; Kristi Rau2; Allison Strate, RN2; Frank L. Greenway, MD3; Donna H. Ryan, MD3; Donald Williamson, PhD3; Brandi Armand, LPN; Jennifer Arceneaux; Amy Bachand, MA; Michelle Begnaud, LDN, RD, CDE; Betsy Berhard; Elizabeth Caderette; Barbara Cerniauskas, LDN, RD, CDE; David Creel, MA; Diane Crow; Crystal Duncan; Helen Guay, LDN, LPC, RD; Carolyn Johnson, Lisa Jones; Nancy Kora; Kelly LaFleur; Kim Landry; Missy Lingle; Jennifer Perault; Cindy Puckett; Mandy Shipp, RD; Marisa Smith; Elizabeth Tucker
Cora E. Lewis, MD, MSPH1; Sheikilya Thomas MPH2; Monika Safford, MD3; Vicki DiLillo, PhD; Charlotte Bragg, MS, RD, LD; Amy Dobelstein; Stacey Gilbert, MPH; Stephen Glasser, MD3; Sara Hannum, MA; Anne Hubbell, MS; Jennifer Jones, MA; DeLavallade Lee; Ruth Luketic, MA, MBA, MPH; L. Christie Oden; Janet Raines, MS; Cathy Roche, RN, BSN; Janet Truman; Nita Webb, MA; Casey Azuero, MPH; Jane King, MLT; Andre Morgan
David M. Nathan, MD1; Enrico Cagliero, MD3; Kathryn Hayward, MD3; Heather Turgeon, RN, BS, CDE2; Linda Delahanty, MS, RD3; Ellen Anderson, MS, RD3; Laurie Bissett, MS, RD; Valerie Goldman, MS, RD; Virginia Harlan, MSW; Theresa Michel, DPT, DSc, CCS; Mary Larkin, RN; Christine Stevens, RN; Kylee Miller, BA; Jimmy Chen, BA; Karen Blumenthal, BA; Gail Winning, BA; Rita Tsay, RD; Helen Cyr, RD; Maria Pinto
Edward S. Horton, MD1; Sharon D. Jackson, MS, RD, CDE2; Osama Hamdy, MD, PhD3; A. Enrique Caballero, MD3; Sarah Bain, BS; Elizabeth Bovaird, BSN, RN; Barbara Fargnoli, MS,RD; Jeanne Spellman, BS, RD; Ann Goebel-Fabbri, PhD; Lori Lambert, MS, RD; Sarah Ledbury, MEd, RD; Maureen Malloy, BS; Kerry Ovalle, MS, RCEP, CDE
James O. Hill, PhD1; Marsha Miller, MS, RD2; Brent Van Dorsten, PhD3; Judith Regensteiner, PhD3; Ligia Coelho, BS; Paulette Cohrs, RN, BSN; Susan Green; April Hamilton, BS, CCRC; Jere Hamilton, BA; Eugene Leshchinskiy; Lindsey Munkwitz, BS; Loretta Rome, TRS; Terra Worley, BA; Kirstie Craul, RD,CDE; Sheila Smith, BS
John P. Foreyt, PhD1; Rebecca S. Reeves, DrPH, RD2; Henry Pownall, PhD3; Ashok Balasubramanyam, MBBS3; Peter Jones, MD3; Michele Burrington, RD, RN; Chu-Huang Chen, MD, PhD; Allyson Clark Gardner, MS, RD; Molly Gee, MEd, RD; Sharon Griggs; Michelle Hamilton; Veronica Holley; Jayne Joseph, RD; Julieta Palencia, RN; Jennifer Schmidt; Carolyn White
Karen C. Johnson, MD, MPH1; Carolyn Gresham, RN2; Stephanie Connelly, MD, MPH3; Amy Brewer, RD, MS; Mace Coday, PhD; Lisa Jones, RN; Lynne Lichtermann, RN, BSN; Shirley Vosburg, RD, MPH; and J. Lee Taylor, MEd, MBA
Robert W. Jeffery, PhD1; Carolyn Thorson, CCRP2; John P. Bantle, MD3; J. Bruce Redmon, MD3; Richard S. Crow, MD3; Scott Crow, MD3; Susan K Raatz, PhD, RD3; Kerrin Brelje, MPH, RD; Carolyne Campbell; Jeanne Carls, MEd; Tara Carmean-Mihm, BA; Julia Devonish, MS; Emily Finch, MA; Anna Fox, MA; Elizabeth Hoelscher, MPH, RD, CHES; La Donna James; Vicki A. Maddy, BS, RD; Therese Ockenden, RN; Birgitta I. Rice, MS, RPh, CHES; Tricia Skarphol, BS; Ann D. Tucker, BA; Mary Susan Voeller, BA; Cara Walcheck, BS, RD
Xavier Pi-Sunyer, MD1; Jennifer Patricio, MS2; Stanley Heshka, PhD3; Carmen Pal, MD3; Lynn Allen, MD; Lolline Chong, BS, RD; Marci Gluck, PhD; Diane Hirsch, RNC, MS, CDE; Mary Anne Holowaty, MS, CN; Michelle Horowitz, MS, RD; Nancy Rau, MS, RD, CDE; Dori Brill Steinberg, BS
Thomas A. Wadden, PhD1; Barbara J Maschak-Carey, MSN, CDE2; Robert I. Berkowitz, MD3; Seth Braunstein, MD, PhD3; Gary Foster, PhD3; Henry Glick, PhD3; Shiriki Kumanyika, PhD, RD, MPH3; Stanley S. Schwartz, MD3; Michael Allen, RN; Yuliis Bell; Johanna Brock; Susan Brozena, MD; Ray Carvajal, MA; Helen Chomentowski; Canice Crerand, PhD; Renee Davenport; Andrea Diamond, MS, RD; Anthony Fabricatore, PhD; Lee Goldberg, MD; Louise Hesson, MSN, CRNP; Thomas Hudak, MS; Nayyar Iqbal, MD; LaShanda Jones-Corneille, PhD; Andrew Kao, MD; Robert Kuehnel, PhD; Patricia Lipschutz, MSN; Monica Mullen, RD, MPH
John M. Jakicic, PhD1, David E. Kelley, MD1; Jacqueline Wesche-Thobaben, RN, BSN, CDE2; Lewis H. Kuller, MD, DrPH3; Andrea Kriska, PhD3; Amy D. Otto, PhD, RD, LDN3, Lin Ewing, PhD, RN3, Mary Korytkowski, MD3, Daniel Edmundowicz, MD3; Monica E. Yamamoto, DrPH, RD, FADA3; Rebecca Danchenko, BS; Barbara Elnyczky; David O. Garcia, MS; George A. Grove, MS; Patricia H. Harper, MS, RD, LDN; Susan Harrier, BS; Nicole L. Helbling, MS, RN; Diane Ives, MPH; Juliet Mancino, MS, RD, CDE, LDN; Anne Mathews, PhD, RD, LDN; Tracey Y. Murray, BS; Joan R. Ritchea; Susan Urda, BS, CTR; Donna L. Wolf, PhD
Rena R. Wing, PhD1; Renee Bright, MS2; Vincent Pera, MD3; John Jakicic, PhD3; Deborah Tate, PhD3; Amy Gorin, PhD3; Kara Gallagher, PhD3; Amy Bach, PhD; Barbara Bancroft, RN, MS; Anna Bertorelli, MBA, RD; Richard Carey, BS; Tatum Charron, BS; Heather Chenot, MS; Kimberley Chula-Maguire, MS; Pamela Coward, MS, RD; Lisa Cronkite, BS; Julie Currin, MD; Maureen Daly, RN; Caitlin Egan, MS; Erica Ferguson, BS, RD; Linda Foss, MPH; Jennifer Gauvin, BS; Don Kieffer, PhD; Lauren Lessard, BS; Deborah Maier, MS; JP Massaro, BS; Tammy Monk, MS; Rob Nicholson, PhD; Erin Patterson, BS; Suzanne Phelan, PhD; Hollie Raynor, PhD, RD; Douglas Raynor, PhD; Natalie Robinson, MS, RD; Deborah Robles; Jane Tavares, BS
Steven M. Haffner, MD1; Maria G. Montez, RN, MSHP, CDE2; Carlos Lorenzo, MD3; Charles F. Coleman, MS, RD; Domingo Granado, RN; Kathy Hathaway, MS, RD; Juan Carlos Isaac, RC, BSN; Nora Ramirez, RN, BSN; Ronda Saenz, MS, RD
Steven Kahn MB, ChB1; Brenda Montgomery, RN, MS, CDE2; Robert Knopp, MD3; Edward Lipkin, MD3; Dace Trence, MD3; Terry Barrett, BS; Joli Bartell, BA; Diane Greenberg, PhD; Anne Murillo, BS; Betty Ann Richmond, MEd; Jolanta Socha, BS; April Thomas, MPH, RD; Alan Wesley, BA
William C. Knowler, MD, DrPH1; Paula Bolin, RN, MC2; Tina Killean, BS2; Cathy Manus, LPN3; Jonathan Krakoff, MD3; Jeffrey M. Curtis, MD, MPH3; Justin Glass, MD3; Sara Michaels, MD3; Peter H. Bennett, MB, FRCP3; Tina Morgan3; Shandiin Begay, MPH; Paul Bloomquist, MD; Teddy Costa, BS; Bernadita Fallis RN, RHIT, CCS; Jeanette Hermes, MS,RD; Diane F. Hollowbreast; Ruby Johnson; Maria Meacham, BSN, RN, CDE; Julie Nelson, RD; Carol Percy, RN; Patricia Poorthunder; Sandra Sangster; Nancy Scurlock, MSN, ANP-C, CDE; Leigh A. Shovestull, RD, CDE; Janelia Smiley; Katie Toledo, MS, LPC; Christina Tomchee, BA; Darryl Tonemah, PhD
Mark A. Espeland, PhD1; Judy L. Bahnson, BA, CCRP3; Lynne E. Wagenknecht, DrPH3; David Reboussin, PhD3; W. Jack Rejeski, PhD3; Alain G. Bertoni, MD, MPH3; Wei Lang, PhD3; Michael S. Lawlor, PhD3; David Lefkowitz, MD3; Gary D. Miller, PhD3; Patrick S. Reynolds, MD3; Paul M. Ribisl, PhD3; Mara Vitolins, DrPH3; Haiying Chen, PhD3; Delia S. West, PhD3; Lawrence M. Friedman, MD3; Brenda L. Craven, MS, CCRP2; Kathy M. Dotson, BA2; Amelia Hodges, BS, CCRP2; Carrie C. Williams, BS, CCRP2; Andrea Anderson, MS; Jerry M. Barnes, MA, Mary Barr; Daniel P. Beavers, PhD; Tara Beckner; Cralen Davis, MS; Thania Del Valle-Fagan, MD; Patricia A. Feeney, MS; Candace Goode; Jason Griffin, BS; Lea Harvin, BS; Patricia Hogan, MS; Sarah A. Gaussoin, MS; Mark King, BS; Kathy Lane, BS; Rebecca H. Neiberg, MS; Michael P. Walkup, MS; Karen Wall, AAS; Terri Windham
Robert Moran, PhD1
Richard Foushee, PhD; Nancy J. Hall, MA
Mary Evans, PhD; Barbara Harrison, MS; Van S. Hubbard, MD, PhD; Susan Z.Yanovski, MD; Robert Kuczmarski, PhD
Lawton S. Cooper, MD, MPH; Peter Kaufman, PhD, FABMR
Edward W. Gregg, PhD; David F. Williamson, PhD; Ping Zhang, PhD
This study is supported by the Department of Health and Human Services through the following cooperative agreements from the National Institutes of Health: DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, and DK56992. The following federal agencies have contributed support: National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; Office of Research on Women’s Health; the Centers for Disease Control and Prevention; and the Department of Veterans Affairs. This research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. The Indian Health Service (I.H.S.) provided personnel, medical oversight, and use of facilities. The opinions expressed in this paper are those of the authors and do not necessarily reflect the views of the I.H.S. or other funding sources.
Additional support was received from The Johns Hopkins Medical Institutions Bayview General Clinical Research Center (M01RR02719); the Massachusetts General Hospital Mallinckrodt General Clinical Research Center and the Massachusetts Institute of Technology General Clinical Research Center (M01RR01066); the University of Colorado Health Sciences Center General Clinical Research Center (M01RR00051) and Clinical Nutrition Research Unit (P30 DK48520); the University of Tennessee at Memphis General Clinical Research Center (M01RR0021140); the University of Pittsburgh General Clinical Research Center (GCRC) (M01RR000056), the Clinical Translational Research Center (CTRC) funded by the Clinical & Translational Science Award (UL1 RR 024153) and NIH grant (DK 046204); and the Frederic C. Bartter General Clinical Research Center (M01RR01346)
The following organizations have committed to make major contributions to Look AHEAD: FedEx Corporation; Health Management Resources; LifeScan, Inc., a Johnson & Johnson Company; OPTIFAST® of Nestle HealthCare Nutrition, Inc.; Hoffmann-La Roche Inc.; Abbott Nutrition; and Slim-Fast Brand of Unilever North America.
All other Look AHEAD staffs are listed alphabetically by site.
Trial Registration: clinicaltrials.gov Identifier: NCT00017953